RNA extended interventional nucleic acid longitudinal study: Clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9‐year follow‐up
Cancer Cytopathology · 2024
DOI: 10.1002/cncy.22895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, 2024. Verfasst von Rosario Granados und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hospital Universitario de Getafe, Madrid, Spain. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Early Detection of Cancer, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hologic Deutschland GmbH in., The Foundation for Biomedical Research Hospital Universitario de Getafe.
Abstract (Originalsprache)
Background
There is a need for additional longitudinal studies with the Aptima messenger RNA human papillomavirus test (AHPV) to support the safety of extended screening intervals. RNA‐based extended interventional nucleic acid (REINA) provides relevant information on the clinical performance of AHPV.
Methods
This is a longitudinal prospective analysis of 1538 participants after AHPV and liquid‐based cytology (LBC) co‐test complemented with REINA interventional protocol with a second co‐test 4 years after negative screening on 2000 women. Diagnostic accuracy and cumulative risks for CIN2+ up to 9 years were calculated for all test combinations.
Results
Sensitivity and specificity for CIN2+ were 96.9% and 88.0% for AHPV and 72.3% and 92.0% for LBC. Negative predictive value (NPV) and positive predictive value (PPV) of AHPV were 99.9% and 23.6%. The 5‐ and 9‐year risks of AHPV‐negative women were 0.4% and 1.0% (CIN2+) and 0.3% and 0.7% (CIN3+), a 73% and 64% lower risk than with negative LBC ( p ≤ .002). REINA participants with an AHPV‐positive result at second co‐test after a negative AHPV in first round had a significantly lower 5‐year risk of CIN2+ (11.1%) than AHPV‐positive women with unknown HPV history (29.5%).
Conclusions
Currently, this constitutes the longest European longitudinal study with AHPV testing in screening population. It reveals 99.9% NPV and a significant protective effect of a previous negative test 5 years after a new HPV infection. These findings support the safety of Aptima for screening intervals beyond 5 years. The risk of disease is lower 9 years after a negative AHPV test than 3 years after a negative LBC. High specificity and PPV of Aptima may benefit controlling overtreatment and colposcopy referrals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Hospital Universitario de Getafe, Madrid, Spain.
- Universidad Europea de Madrid, Madrid, Spain.
- Department of Gynecology, Hospital Universitario de Getafe, Madrid, Spain.
ORCID-Profile: Rosario Granados
Förderung
- Hologic Deutschland GmbH in.
- The Foundation for Biomedical Research Hospital Universitario de Getafe
Zitieren
APA
Granados, R., Duarte, J. A., Luján, D. R., Gutierrez-Pecharromán, A. M., Solís, I., Molpeceres, L., Bajo, P., Palencia, E., & Martín, N. (2024). RNA extended interventional nucleic acid longitudinal study: Clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9‐year follow‐up. Cancer Cytopathology. https://doi.org/10.1002/cncy.22895
Vancouver
Granados R, Duarte JA, Luján DR, Gutierrez-Pecharromán AM, Solís I, Molpeceres L, et al. RNA extended interventional nucleic acid longitudinal study: Clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9‐year follow‐up. Cancer Cytopathology. 2024. doi:10.1002/cncy.22895
BibTeX
@article{Granados2024,
author = {Granados, Rosario and Duarte, Joanny A and Luján, David R and Gutierrez-Pecharromán, Ana M and Solís, Isabel and Molpeceres, Lourdes and Bajo, Paloma and Palencia, Elsa and Martín, Nuria},
title = {RNA extended interventional nucleic acid longitudinal study: Clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9‐year follow‐up},
journal = {Cancer Cytopathology},
year = {2024},
doi = {10.1002/cncy.22895}
}
EUVIMED